Handelsbanken Fonder Ab Immuno Gen, Inc. Transaction History

Handelsbanken Fonder Ab

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	BUY	$12.46 - $29.95 $57,316 - $137,770	4,600 Added 10.43%	48,700 $1.44 Million
Q3 2023 Oct 19, 2023	BUY	$14.09 - $19.87 $128,219 - $180,817	9,100 Added 26.0%	44,100 $700,000
Q2 2023 Aug 02, 2023	BUY	$3.75 - $20.05 $25,500 - $136,340	6,800 Added 24.11%	35,000 $660,000
Q4 2022 Feb 07, 2023	BUY	$4.55 - $6.31 $51,870 - $71,934	11,400 Added 67.86%	28,200 $140,000
Q3 2022 Oct 27, 2022	SELL	$4.48 - $6.47 $112,000 - $161,750	-25,000 Reduced 59.81%	16,800 $80,000
Q2 2022 Aug 03, 2022	SELL	$3.15 - $5.76 $4,725 - $8,640	-1,500 Reduced 3.46%	41,800 $188,000
Q2 2021 Aug 03, 2021	BUY	$5.79 - $8.6 $250,707 - $372,380	43,300 New	43,300 $285,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.